AbbVie received European Commission approval for Aquipta (atogepant) on June 2, 2026. This authorization covers the acute treatment of migraine with or without aura in adults. Patients may now use the oral medication as needed to stop active migraine attacks.
The decision expands Aquipta’s existing EU label for preventing chronic and episodic migraines. This previous approval applied to adults experiencing at least four migraine days per month.
Results from the Phase 3 ECLIPSE trial supported the latest approval. The study demonstrated that Aquipta provided statistically significant pain freedom at two hours compared to a placebo.
This dual approval for acute and preventive use increases treatment versatility for millions of European patients. The expansion strengthens AbbVie’s neurology portfolio and competitive position in the migraine market.